Oxford Biomedica Balance Sheet Health
Financial Health criteria checks 4/6
Oxford Biomedica has a total shareholder equity of £71.2M and total debt of £39.7M, which brings its debt-to-equity ratio to 55.8%. Its total assets and total liabilities are £245.0M and £173.8M respectively.
Key information
55.8%
Debt to equity ratio
UK£39.74m
Debt
| Interest coverage ratio | n/a |
| Cash | UK£81.41m |
| Equity | UK£71.22m |
| Total liabilities | UK£173.75m |
| Total assets | UK£244.97m |
Recent financial health updates
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
Oct 19
Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn
Jun 29Recent updates
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
Oct 19Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
Aug 23Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 15Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings
May 02We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn
Jun 29Financial Position Analysis
Short Term Liabilities: OXB's short term assets (£138.9M) exceed its short term liabilities (£59.1M).
Long Term Liabilities: OXB's short term assets (£138.9M) exceed its long term liabilities (£114.6M).
Debt to Equity History and Analysis
Debt Level: OXB has more cash than its total debt.
Reducing Debt: OXB's debt to equity ratio has increased from 0% to 55.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OXB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OXB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 19:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford Biomedica plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rick Bienkowski | Cantor Fitzgerald & Co. |
| Susie Jana | Edison Investment Research |
| Jens Lindqvist | Investec Bank plc (UK) |